Over on ST someone is posting a claim (posted on some other site) that Eli Lilly is going to buy Sintx for $5 billion. There is nothing to substantiate this claim and i wonder if this is being pushed to counter a post from 2011, which you can actually verify, stating that Zimmer intended to acquire Amedica (Now Sintx) for its technology. This claim about Eli Lilly buyout could be purposeful misinformation to try to discredit Sintx ties to Zimmer which i detail in various posts below. The same funds manipulating the stock would be the most likely source of this misinformation. Something to remember/know, is when Sintx IPO'd, all references to personnel with connections to Zimmer was removed or not disclosed. Specifically the current CEO and former Chairman connections to Zimmer. Its interesting but TAman87 called it a lie that needs to be investigated by the SEC but he doesnt say that about this following quote about Zimmer wanting to acquire Amedica (Sintx). Also this same account that is posting this supposed buyout is claiming that Sintx is changing its ISIN for M&A purposes but in fact its changing its ISIN because of the RS.
AnonymousMay 24, 2011 at 3:42 PM Zimmer is looking at purchasing Amedica flat out for their techology to bolster sales in spine through licensing and to purchase the next generation of hip and knee implants. You heard it here on TSB.
Unlike the Eli Lilly post, this statement can be verified and it actually provides a solid reason for why Zimmer would acquire Amedica (now Sintx). As Sintx IP has vastly expanded over the years from when this statement was made, i'd say that Zimmer Biomet would acquire Sintx to license its tech as well as use Si3N4 for arthroplasty products.
A basic roadmap laid out of Zimmer's intentions for Sintx back in 2011. This quote predates Sintx vast IP portfolio expansion. Any markets Zimmer Biomet does not currently participate in, that Sintx does, represents potential markets Zimmer Biomet can utilize Sintx to bolster its revenue through licensing as well as diversify those revenue sources.
AnonymousMay 24, 2011 at 3:42 PM Zimmer is looking at purchasing Amedica flat out for their techology to bolster sales in spine through licensing and to purchase the next generation of hip and knee implants. You heard it here on TSB.
Silicon nitride, silicon carbide and diamond-like carbon as non-oxide ceramics are considered to be the new generation of materials used in hip prosthetics
Mr Bond, they have a saying in Chicago: 'Once is happenstance. Twice is coincidence. The third time it's enemy action'.
One is an incident, two is a coincidence, three's a pattern, and four is enough for a warrant
========================================
Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application
examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
Silicon nitride, silicon carbide and diamond-like carbon as non-oxide ceramics are considered to be the new generation of materials used in hip prosthetics, particularly in the manufacture of acetabular cups, due to their excellent biocompatibility, osteointegration, and tribological and mechanical properties, but all three materials need more study. However, silicon nitride is the nearest to commercialization, through businesses such as Amedica Corp. and SyntX Technologies